Solriamfetol + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Excessive Daytime Sleepiness
Conditions
Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function
Trial Timeline
May 17, 2021 → Sep 19, 2022
NCT ID
NCT04789174About Solriamfetol + Placebo
Solriamfetol + Placebo is a approved stage product being developed by Axsome Therapeutics for Excessive Daytime Sleepiness. The current trial status is completed. This product is registered under clinical trial identifier NCT04789174. Target conditions include Excessive Daytime Sleepiness, Obstructive Sleep Apnea, Impaired Cognitive Function.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06170970 | Phase 2 | Recruiting |
| NCT04789174 | Approved | Completed |
Competing Products
8 competing products in Excessive Daytime Sleepiness
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + PF-03654746 | Pfizer | Phase 2 | 51 |
| JZP-110 | Jazz Pharmaceuticals | Phase 2 | 49 |
| Solriamfetol 150 MG + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol Oral Tablet + Placebo | Axsome Therapeutics | Approved | 82 |
| Fibrin Sealant Grifols + EVICEL | Grifols | Phase 3 | 74 |
| ORX142 Tablets | Centessa Pharmaceuticals | Phase 1 | 28 |
| VSF-173 | Vanda Pharmaceuticals | Phase 2 | 44 |